1. Home
  2. POET vs TBPH Comparison

POET vs TBPH Comparison

Compare POET & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo POET Technologies Inc.

POET

POET Technologies Inc.

HOLD

Current Price

$6.83

Market Cap

843.0M

Sector

Technology

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$13.69

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POET
TBPH
Founded
1972
2013
Country
Canada
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
843.0M
1.0B
IPO Year
2008
2013

Fundamental Metrics

Financial Performance
Metric
POET
TBPH
Price
$6.83
$13.69
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$20.20
AVG Volume (30 Days)
5.5M
588.0K
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.88
Revenue
N/A
$15,386,000.00
Revenue This Year
$2,939.08
$70.90
Revenue Next Year
$710.17
N/A
P/E Ratio
N/A
$15.77
Revenue Growth
N/A
N/A
52 Week Low
$3.10
$7.90
52 Week High
$9.41
$21.03

Technical Indicators

Market Signals
Indicator
POET
TBPH
Relative Strength Index (RSI) 58.24 22.66
Support Level $5.05 $13.58
Resistance Level $7.66 $14.76
Average True Range (ATR) 0.45 0.94
MACD 0.18 -0.58
Stochastic Oscillator 76.00 8.27

Price Performance

Historical Comparison
POET
TBPH

About POET POET Technologies Inc.

POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: